ArticleWorld journal of gastroenterology2013
Middle segmental pancreatectomy: a safe and organ-preserving option for benign and low-grade malignant lesions.
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Overall Postoperative Morbidity and Pancreatic Fistula Are Relatively Higher after Central Pancreatectomy than Distal Pancreatic Resection: A Systematic Review and Meta-Analysis.BioMed research international · 2020Pooled it
- Central pancreatectomy: a comprehensive, up-to-date meta-analysis.Langenbeck's archives of surgery · 2019Pooled it
- Robot-assisted laparoscopic versus open middle pancreatectomy: short-term results of a randomized controlled trial.Surgical endoscopy · 2017Trial
- Predicting severity of inpatient acute cholangitis: combined neutrophil-to-lymphocyte ratio and prognostic nutritional index.BMC gastroenterology · 2024Article
- Central pancreatectomy for benign or low-grade malignant pancreatic tumors in the neck and body of the pancreas.World journal of gastrointestinal surgery · 2022Article
- Minimally invasive (laparoscopic and robot-assisted) versus open approach for central pancreatectomies: a single-center experience.Surgical endoscopy · 2022Article
- Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: A case report.Medicine · 2019Article
- Clinical efficacy of middle pancreatectomy contrasts distal pancreatectomy: a single-institution experience and review of literature.ANZ journal of surgery · 2019Article
- Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study.Langenbeck's archives of surgery · 2019Article
- Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.Reviews in endocrine & metabolic disorders · 2018Review
- Robotic central pancreatectomy.Journal of visualized surgery · 2017Review
- Median Pancreatectomy Done in a Rural Medical College - A Case Report.Indian journal of surgical oncology · 2016Article
- Minimally invasive surgical approach to pancreatic malignancies.World journal of gastrointestinal oncology · 2015Review
- Pancreatic Neuroendocrine Tumors: an Update.The Indian journal of surgery · 2015Article
- Update on pancreatic neuroendocrine tumors.Gland surgery · 2014Review
- Laparoscopic central pancreatectomy: Our technique and long-term results in 14 patients.Journal of minimal access surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the feasibility and safety of middle segmental pancreatectomy (MSP) compared with pancreaticoduodenectomy (PD) and extended distal pancreatectomy (EDP).
methodsWe studied retrospectively 36 cases that underwent MSP, 44 patients who underwent PD, and 26 who underwent EDP with benign or low-grade malignant lesions in the mid-portion of the pancreas, between April 2003 and December 2009 in Ruijin Hospital. The perioperative outcomes and long-term outcomes of MSP were compared with those of EDP and PD. Perioperative outcomes included operative time, intraoperative hemorrhage, transfusion, pancreatic fistula, intra-abdominal abscess/infection, postoperative bleeding, reoperation, mortality, and postoperative hospital time. Long-term outcomes, including tumor recurrence, new-onset diabetes mellitus (DM), and pancreatic exocrine insufficiency, were evaluated.
resultsIntraoperative hemorrhage was 316.1 ± 309.6, 852.2 ± 877.8 and 526.9 ± 414.5 mL for the MSP, PD and EDP groups, respectively (P < 0.05). The mean postoperative daily fasting blood glucose level was significantly lower in the MSP group than in the EDP group (6.3 ± 1.5 mmol/L vs 7.3 ± 1.5 mmol/L, P < 0.05). The rate of pancreatic fistula was higher in the MSP group than in the PD group (42% vs 20.5%, P = 0.039), all of the fistulas after MSP corresponded to grade A (9/15) or B (6/15) and were sealed following conservative treatment. There was no significant difference in the mean postoperative hospital stay between the MSP group and the other two groups. After a mean follow-up of 44 mo, no tumor recurrences were found, only one patient (2.8%) in the MSP group vs five (21.7%) in the EDP group developed new-onset insulin-dependent DM postoperatively (P = 0.029). Moreover, significantly fewer patients in the MSP group than in the PD (0% vs 33.3%, P < 0.001) and EDP (0% vs 21.7%, P = 0.007) required enzyme substitution.
conclusionMSP is a safe and organ-preserving option for benign or low-grade malignant lesions in the neck and proximal body of the pancreas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.